Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6

Human Mutation

Volumn 37, Issue 3, 2016, Pages 315-323

  Qiao, Wanqiong ^a   Yang, Yao ^a   Sebra, Robert ^a   Mendiratta, Geetu ^a   Gaedigk, Andrea ^b,c   Desnick, Robert J ^a   Scott, Stuart A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY KANSAS CITY   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6; Gene duplication; Long read sequencing; Pacific Biosciences; Pharmacogenetics; Pharmacogenomics; Single molecule real time (SMRT) sequencing

Indexed keywords

CYTOCHROME P450 2D6;

ALLELE; ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXON; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HUMAN; INTRON; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SINGLE MOLECULE REAL TIME SEQUENCING; TANDEM REPEAT; VALIDATION STUDY; GENE FREQUENCY; GENETICS;

ALLELES; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS;

EID: 84957970833     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22936     Document Type: Article

References (39)

1. Ammar R, Paton TA, Torti D, Shlien A, Bader GD. 2015. Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000Res 4:17.
2. Ashton PM, Nair S, Dallman T, Rubino S, Rabsch W, Mwaigwisya S, Wain J, O'Grady J. 2015. MinION nanopore sequencing identifies the position and structure of a bacterial antibiotic resistance island. Nat Biotechnol 33:296-300.
3. Breese MR, Liu Y. 2013. NGSUtils: a software suite for analyzing and manipulating next-generation sequencing datasets. Bioinformatics 29:494-496.
4. Chaisson MJ, Tesler G. 2012. Mapping single molecule sequencing reads using basic local alignment with successive refinement (BLASR): application and theory. BMC Bioinformatics 13:238.
5. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC, Clinical Pharmacogenetics Implementation C. 2012. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321-326.
6. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, et al. 2014. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95:376-382.
7. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, et al. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43:491-498.
8. Fang H, Liu X, Ramirez J, Choudhury N, Kubo M, Im HK, Konkashbaev A, Cox NJ, Ratain MJ, Nakamura Y, O'Donnell PH. 2014. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J 14:564-572.
9. Gaedigk A. 2013. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 25:534-553.
10. Gaedigk A, Bradford LD, Alander SW, Leeder JS. 2006. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 34:563-569.
11. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. 2007. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 81:242-251.
12. Gaedigk A, Riffel AK, Leeder JS. 2015. CYP2D6 Haplotype determination using long range allele-specific amplification: resolution of a complex genotype and a discordant genotype involving the CYP2D6*59 allele. J Mol Diagn 17:740-748.
13. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
14. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:442-446.
15. Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. 1990. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773-776.
16. Heim M, Meyer UA. 1990. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532.
17. Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, et al. 2015. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. Br J Clin Pharmacol 80:1122-1130.
18. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, A LL, Skaar TC, Scott SA, et al. 2015. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 98:127-134.
19. Hicks JK, Swen JJ, Gaedigk A. 2014. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 15:218-232.
20. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC, Clinical Pharmacogenetics Implementation C. 2013. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402-408.
21. Hirotsu N, Murakami N, Kashiwagi T, Ujiie K, Ishimaru K. 2010. Protocol: a simple gel-free method for SNP genotyping using allele-specific primers in rice and other plant species. Plant Methods 6:12.
22. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. 1989. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904.
23. Kiyotani K, Mushiroda T, Zembutsu H, Nakamura Y. 2013. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet 58:327-333.
24. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv 1303.3997v2:1-3.
25. Liu J, Huang S, Sun M, Liu S, Liu Y, Wang W, Zhang X, Wang H, Hua W. 2012. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plant Methods 8:34.
26. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. 1977. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2:584-586.
27. Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ, Scott SA. 2013a. Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J 13:558-566.
28. Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA. 2013b. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 13:369-377.
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297-1303.
30. Meier PJ, Mueller HK, Dick B, Meyer UA. 1983. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:682-692.
31. Owen RP, Sangkuhl K, Klein TE, Altman RB. 2009. Cytochrome P450 2D6. Pharmacogenet Genomics 19:559-562.
32. Pratt VM, Zehnbauer B, Wilson JA, Baak R, Babic N, Bettinotti M, Buller A, Butz K, Campbell M, Civalier C, El-Badry A, Farkas DH, et al. 2010. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn 12:835-846.
33. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, et al. 2014. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-227.
34. Ramamoorthy A, Skaar TC. 2011. Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics 12:299-301.
35. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, et al. 2011. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365:709-717.
36. Relling MV, Klein TE. 2011. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 89:464-467.
37. Sim SC, Ingelman-Sundberg M. 2010. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4:278-281.
38. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M. 2001. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 11:417-427.
39. Yang Y, Sebra R, Pullman BS, Qiao W, Peter I, Desnick RJ, Geyer CR, DeCoteau JF, Scott SA. 2015. Quantitative and multiplexed DNA methylation analysis using long-read single-molecule real-time bisulfite sequencing (SMRT-BS). BMC Genomics 16:350.